Strategic Partnerships Myriad Neuroscience has active and recent partnership activity with mental health providers and clinics (Brookfield/HIAAH partnerships in 2023, Catalyst Psychiatry in 2025), indicating a receptive market for pharmacogenomic testing services. Leverage these collaboration patterns to approach similar behavioral health networks and specialty clinics to expand test adoption.

Pharmacogenomics Focus The company specializes in pharmacogenomics to guide psychotropic medication decisions, with the GeneSight test developed in partnership with Mayo Clinic and Cincinnati Children’s Hospital. This positions the product as a scientifically robust, evidence-based tool ideal for payors and providers looking to optimize psychiatric pharmacotherapy and reduce trial-and-error prescribing.

Growth Through Outreach Leadership hires in 2022 such as the SVP/CMO and a General Manager of Oncology suggest a push toward expanding market reach and commercial execution. This indicates ongoing investments in sales and marketing capabilities that can be leveraged to gain access to new regional health systems.

Pilot and Monitor Programs The GeneSight Mental Health Monitor study (2023) signals an emphasis on outcomes data and behavioral risk monitoring. There is an opportunity to position the company as a provider of value-based care data, offering payers and providers evidence on improved safety and efficacy to justify broader adoption.

Revenue Opportunity Current revenue range and mid-sized employee footprint (51-200 employees) alongside ongoing partnerships indicate reachable mid-market clinical networks and practices. Target mid-sized behavioral health groups and specialty clinics that can scale PGx testing across multiple clinicians, supported by existing regulatory-lab capabilities and established collaborations.